The brief

Analyst view

• Survodutide met phase 3 endpoints in SYNCHRONIZE-1 (April 2026) and SYNCHRONIZE-2 (October 2026).
• SYNCHRONIZE-1: 16.6% weight loss with 63% liver fat reduction versus placebo.
• Boehringer Ingelheim licensed Survodutide globally from Zealand Pharma; leads development.

Technical approach

As reported

Dual agonism

Glucagon and GLP-1 receptors

Survodutide activates glucagon (energy expenditure and fat burning) and GLP-1 (appetite suppression). Targets weight loss from two directions.

Liver metabolism

Targeted liver fat reduction

Glucagon agonism preferentially reduces liver fat (63% reduction in phase 3), addressing metabolic dysfunction-associated fatty liver disease directly.

Lean mass preservation

Minimize muscle loss

The combination preserves lean muscle during weight loss, an advantage over GLP-1-only approaches.